Suppr超能文献

关于有机阳离子转运体1(OCT1)变体活性及使用Oct1/2基因敲除小鼠的知识拓展

Expansion of Knowledge on OCT1 Variant Activity and Using Oct1/2 Mice.

作者信息

Morse Bridget L, Chen Lisa Hong, Catlow John T, Fallon John K, Smith Philip C, Hillgren Kathleen M

机构信息

Drug Disposition, Eli Lilly and Company, Indianapolis, IN, United States.

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

出版信息

Front Pharmacol. 2021 Feb 15;12:631793. doi: 10.3389/fphar.2021.631793. eCollection 2021.

Abstract

The role of organic cation transporter 1 (OCT1) in humans is gaining attention as data emerges regarding its role in physiology, drug exposure, and drug response. OCT1 variants with decreased function correlate well with altered exposure of multiple OCT1 substrates in variant carriers. In the current research, we investigate mechanisms behind activity of OCT1 variants by generating cell lines expressing known OCT1 variants and quantifying membrane OCT1 protein expression with corresponding OCT1 activity and kinetics. Oct knockout mice have provided additional insight into the role of Oct1 in the liver and have reproduced effects of altered OCT1 activity observed in the clinic. To assess the complex effect of Oct1 depletion on pharmacokinetics of prodrug proguanil and its active moiety cycloguanil, both of which are OCT1 substrates, Oct1/2 mice were used. Decreased membrane expression of OCT1 was demonstrated for all variant cell lines, although activity was substrate-dependent, as reported previously. Lack of change in activity for OCT1*2 resulted in increased intrinsic activity per pmol of OCT1 protein, particularly for sumatriptan but also for proguanil and cycloguanil. Similar to that reported in humans with decreased OCT1 function, systemic exposure of proguanil was minimally affected in Oct1/2 mice. However, proguanil liver partitioning and exposure decreased. Cycloguanil exposure decreased following proguanil administration in Oct1/2 mice, as did the systemic metabolite:parent ratio. When administered directly, systemic exposure of cycloguanil decreased slightly; however liver partitioning and exposure were decreased in Oct1/2 mice. Unexpectedly, following proguanil administration, the metabolite ratio in the liver changed only minimally, and liver partitioning of cycloguanil was affected in Oct1/2 mice to a lesser extent following proguanil administration than direct administration of cycloguanil. In conclusion, these and data offer additional complexity in understanding mechanisms of OCT1 variant activity as well as the effects of these variants . From cell lines, it is apparent that intrinsic activity is not directly related to OCT1 membrane expression. Additionally, in situations with a more complicated role of OCT1 in drug pharmacokinetics there is difficulty translating impact simply from intrinsic activity from cellular data.

摘要

随着有关有机阳离子转运体1(OCT1)在生理学、药物暴露和药物反应中作用的数据不断涌现,其在人类中的作用日益受到关注。功能降低的OCT1变体与变体携带者中多种OCT1底物暴露的改变密切相关。在当前的研究中,我们通过构建表达已知OCT1变体的细胞系,并利用相应的OCT1活性和动力学对膜OCT1蛋白表达进行定量,来探究OCT1变体活性背后的机制。Oct基因敲除小鼠为深入了解Oct1在肝脏中的作用提供了额外的线索,并重现了临床上观察到的OCT1活性改变的效应。为了评估Oct1缺失对前药氯胍及其活性部分环氯胍药代动力学的复杂影响(二者均为OCT1底物),研究使用了Oct1/2小鼠。正如之前报道的那样,所有变体细胞系的OCT1膜表达均降低,尽管活性具有底物依赖性。OCT1*2活性无变化导致每皮摩尔OCT1蛋白的内在活性增加,尤其是对于舒马曲坦,对氯胍和环氯胍也是如此。与OCT1功能降低的人类中报道的情况类似,Oct1/2小鼠中氯胍的全身暴露受到的影响最小。然而,氯胍在肝脏中的分布和暴露减少。在Oct1/2小鼠中,给予氯胍后环氯胍的暴露减少,全身代谢物与母体的比例也降低。直接给药时,环氯胍的全身暴露略有下降;然而,Oct1/2小鼠中环氯胍在肝脏中的分布和暴露减少。出乎意料的是,给予氯胍后,肝脏中的代谢物比例变化很小,并且与直接给予环氯胍相比,Oct1/2小鼠在给予氯胍后环氯胍在肝脏中的分布受到的影响较小。总之,这些数据为理解OCT1变体活性机制以及这些变体的影响增添了更多复杂性。从细胞系中可以明显看出,内在活性与OCT1膜表达没有直接关系。此外,在OCT1在药物药代动力学中作用更为复杂的情况下,很难仅从细胞数据中的内在活性来推断其影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2db/7917185/6feab45a7683/fphar-12-631793-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验